Factors on Therapeutic Drug Monitoring & Safety of Voriconazole in

Status Recruiting

Clinical Trial Summary

This was a prospective clinical study that all voriconazole-treated adult Chinese patients with invasive pulmonary infection admitted to Zhengzhou Central Hospital affiliated to Zhengzhou University from July 2018 to June 2023. The initial voriconazole serum trough concentration, Correlation of various factors, and risk prediction factors for voriconazole serum trough concentration and hepatotoxicity were compared between elderly and non-elderly patients.

Clinical Trial Description

A prospective observational study was conducted from July 2018 to June 2023 in Zhengzhou Central Hospital Affiliated to Zhengzhou University. This study was carried out in accordance with the following criteria: (1) patients who met the criteria for diagnosis of IFI, (2) age ≥ 18 years, (3) The duration of VCZ treatment course ≥ 7 days. Patients were excluded who fulfilled any of the following criteria: (1) Patients who allergic to VCZ, (2) use other anti-fungal drugs during the use of VCZ, (3) do not qualify for blood sampling monitored by blood concentration, (4) pregnant or lactating women, (5) patients who haven't completely and accurately efficacy and safety data, (6) patients who are treated with a combination of liver enzyme inducers and inhibitors (carbamazepine, phenobarbital, phenytoin, cimetidine, rifampin, rifapentine, rifabutin, and so on),(7) patients who are treated with a combination of Paxlovid or Azvudine. Grouping: Patients were divided into the elderly group (group A, ≥ 60 years) and the non-elderly group (group B, < 60 years) according to ages. All the recruited patients were treated with voriconazole. Voriconazole was intravenously administered 2 times at the loading dose of 6 mg/Kg or orally administered 2 times at the loading dose of 400mg at 12h intervals, followed by a maintenance dose of 4 mg/Kg or 200 mg at 12 h intervals. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06137690
Study type	Observational
Source	People's Hospital of Zhengzhou University
Contact	Zhou Li-juan Zhou Li-juan, master
Phone	13838014946
Email	zhou750423@126.com
Status	Recruiting
Phase
Start date	July 1, 2018
Completion date	March 1, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01888458` - Antifungal Prophylaxis With Micafungin After Cord Blood Allogeneic Stem Cell Transplantation (MycaCOORD)	Phase 2
Completed	`NCT00412893` - Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis	Phase 3
Completed	`NCT03066011` - Registry of Patients Treated With Systemic Mold-Active Triazoles
Completed	`NCT04004078` - An Individualized Administration Research of Voriconazole Based on CYP2C19 Gene Polymorphism and TDM
Completed	`NCT01576653` - Prospective Clinical Evaluation of Beta-D-Glucan Assay in Blood and BAL	N/A
Enrolling by invitation	`NCT02510053` - Pharmacokinetics and Pharmacodynamics of Caspofungin (Cancidas ®) and Drug Tolerance of Fungi to Patients With an Invasive Fungal Infection in the Intensive Care Unit	N/A
Completed	`NCT01198236` - Efficacy of Itraconazole as Secondary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation or Chemotherapy With Prior Invasive Fungal Infection	Phase 4
Completed	`NCT01783379` - Pharmacokinetics of Micafungin in Patients Intensive Care Unit
Completed	`NCT01533558` - Pharmacokinetics of Caspofungin (Cancidas ®) Given Intravenously as Therapy to Patients With an Invasive Fungal Infection in the Intensive Care Unit - a Search for Co-variates
Recruiting	`NCT03149562` - Association of Plasma Transfusions and Invasive Fungal Infection
Recruiting	`NCT04665037` - Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)	Phase 2
Terminated	`NCT01148160` - Voriconazole Trough Plasma Levels : Genetic Polymorphism, Efficacy, Safety in Patients With Hematologic Malignancy	N/A
Withdrawn	`NCT01185405` - Voriconazole Plasma Level in Intensive Care Unit (ICU) Patients	N/A
Completed	`NCT00893555` - Pharmacologic Optimization of Voriconazole	Phase 3
Unknown status	`NCT00460330` - Evaluate Three Methods for Diagnosis of Invasive Fungal Infection in Chinese Patients After HSCT	N/A
Completed	`NCT02823132` - Study of the Level of a Protein Which Could Predict the Development of a Fungal Infection in Patients With Acute Leukemia	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Factors on Therapeutic Drug Monitoring and Safety of Voriconazole in Critically Ill Elderly Patients

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms